T2D injectables: 1. Intensifying to first injectable therapy in uncomplicated type 2 diabetes
This education module focuses on a case study of an uncomplicated patient with type 2 diabetes, and the process of intensifying to first injectable therapy. Expert video commentary throughout the module helps step the participant through the decision cycle from the ADA/EASD consensus guidelines for T2D. This module also includes Australian recommendations for patients fasting during Ramadan.
T2D injectables: 2. Intensifying to first injectable therapy in patients with ASCVD risk
In this education module, the participant will work through a case study of a type 2 diabetes patient with ASCVD risk factors. The case study uses the decision cycle from the ADA/EASD consensus guidelines for T2D, and features expert video commentary. The module also discusses patient-related concerns leading to clinical inertia, including useful management decisions when faced with this issue.
T2D injectables: 3. Intensifying to first injectable therapy in patients with established ASCVD
This education module takes a case-study based look at the management of a type 2 diabetes patient with established ASCVD. Featuring expert video commentary, participants will use the decision cycle from the ADA/EASD consensus guidelines for T2D to work through a hypothetical case study. This module also discusses GP-related causes of clinical inertia, as well as additional patient factors such as obesity, low health literacy and diabetes distress.
Rethinking first injectable therapies in type 2 diabetes: A practical approach
This accredited learning module explores how to initiate injectable therapy in a patient with type 2 diabetes who remains above their glycaemic target despite taking dual or triple oral therapy. The activity works through 3 in-depth case-studies: a patient with uncomplicated T2D, a patient with ASCVD risk, and a patient with established ASCVD.
Overcoming barriers to first injectable therapies in type 2 diabetes
Dr Tom Dover (Endocrinologist, Queensland Health) and Dr Ashraf Saleh (GP, Toowomba, Qld) discuss the role of injectable therapies in the ongoing management of type 2 diabetes, and outline methods to reduce barriers and improve patient outcomes.